SAR-442501 is under development for the treatment of achondroplasia and osteochondrodysplasia. It is an antibody acts by targeting Fgfr3. It is administered through subcutaneous route.1

SAR-442501 is under clinical development by Sanofi and currently in Phase I for achondroplasia. According to GlobalData, Phase I drugs for Achondroplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SAR-442501 LoA Report. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.1

On June 17, 2023, Sanofi presented at The Chandler Project’s 5th Annual Achondroplasia Research Conference, PHARMACHON, in Chicago. In their presentation, they discussed achondroplasia and areas of unmet needs surrounding the condition.

  1. SAR-442501 by Sanofi for Achondroplasia: Likelihood of Approval. Pharmaceutical Technology